Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans

Vahid Feiz, Lisa Nijm, Randolph D. Glickman, Lawrence S. Morse, David G. Telander, Susanna S. Park, Christopher R. Polage, Steven M. Christiansen, Majid Moshirfar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)1315-1320
Number of pages6
JournalCornea
Volume32
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Sulfamethoxazole Drug Combination Trimethoprim
Vitrectomy
Cataract
Sulfamethoxazole
Trimethoprim
Temazepam
Microbial Sensitivity Tests
Methicillin-Resistant Staphylococcus aureus
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans. / Feiz, Vahid; Nijm, Lisa; Glickman, Randolph D.; Morse, Lawrence S.; Telander, David G.; Park, Susanna S.; Polage, Christopher R.; Christiansen, Steven M.; Moshirfar, Majid.

In: Cornea, Vol. 32, No. 10, 10.2013, p. 1315-1320.

Research output: Contribution to journalArticle

Feiz, V, Nijm, L, Glickman, RD, Morse, LS, Telander, DG, Park, SS, Polage, CR, Christiansen, SM & Moshirfar, M 2013, 'Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans', Cornea, vol. 32, no. 10, pp. 1315-1320. https://doi.org/10.1097/ICO.0b013e318298ddf8
Feiz, Vahid ; Nijm, Lisa ; Glickman, Randolph D. ; Morse, Lawrence S. ; Telander, David G. ; Park, Susanna S. ; Polage, Christopher R. ; Christiansen, Steven M. ; Moshirfar, Majid. / Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans. In: Cornea. 2013 ; Vol. 32, No. 10. pp. 1315-1320.
@article{b03418bf7438428caaf3a24999951e6f,
title = "Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans",
abstract = "Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt",
keywords = "Aqueous, Bactrim, Endophthalmitis, Sulfamethoxazole, Trimethoprim, Vitrectomy, Vitreous",
author = "Vahid Feiz and Lisa Nijm and Glickman, {Randolph D.} and Morse, {Lawrence S.} and Telander, {David G.} and Park, {Susanna S.} and Polage, {Christopher R.} and Christiansen, {Steven M.} and Majid Moshirfar",
year = "2013",
month = "10",
doi = "10.1097/ICO.0b013e318298ddf8",
language = "English",
volume = "32",
pages = "1315--1320",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans

AU - Feiz, Vahid

AU - Nijm, Lisa

AU - Glickman, Randolph D.

AU - Morse, Lawrence S.

AU - Telander, David G.

AU - Park, Susanna S.

AU - Polage, Christopher R.

AU - Christiansen, Steven M.

AU - Moshirfar, Majid

PY - 2013/10

Y1 - 2013/10

N2 - Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt

AB - Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt

KW - Aqueous

KW - Bactrim

KW - Endophthalmitis

KW - Sulfamethoxazole

KW - Trimethoprim

KW - Vitrectomy

KW - Vitreous

UR - http://www.scopus.com/inward/record.url?scp=84886098908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886098908&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e318298ddf8

DO - 10.1097/ICO.0b013e318298ddf8

M3 - Article

C2 - 23928948

AN - SCOPUS:84886098908

VL - 32

SP - 1315

EP - 1320

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 10

ER -